Figure 10

![Figure 10: Overview of the preclinical-to-clinical evaluation pipeline for edible mushrooms as anti-diabetic nutraceuticals, from in vitro screening through animal models to human trials.]()

> Source: Mohammad Zaki Shamim et al. "Exploring Edible Mushrooms for Diabetes: Unveiling Their Role in Prevention and ." *Molecules (Basel, Switzerland)*, 2023. PMID: [36985818](https://pubmed.ncbi.nlm.nih.gov/36985818/)

<figure>
  <img src="" alt="Overview of the preclinical-to-clinical evaluation pipeline for edible mushrooms as anti-diabetic nutraceuticals, from in vitro screening through animal models to human trials." />
  <figcaption>Figure 10. Overview of the preclinical-to-clinical evaluation pipeline for edible mushrooms as anti-diabetic nutraceuticals, from in vitro screening through animal models to human trials.<br>  Source: Mohammad Zaki Shamim et al. "Exploring Edible Mushrooms for Diabetes: Unveiling Their Role in Prevention and ." <em>Molecules (Basel, Switzerland)</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36985818/">36985818</a></figcaption>
</figure>